FDA allows enrolment to resume in key Avastin adjuvant breast cancer trial
15 December 2009
Malini Guha
Roche (Genentech) has been allowed by the US
FDA to resume enrolment in a key Phase III study of Avastin (bevacizumab) in adjuvant breast cancer after it was halted in September because of cardiac safety issues
Please Login to read the full article.
15 December 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck Serono again tries to FLEX Erbitux's muscle in NSCLC
- US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod
- Chugai expects no impact on top seller Avastin following US breast cancer decision
- US FDA warns of ovarian failure, ONJ with Avastin use
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
